Inflammation Research

, Volume 63, Issue 9, pp 789–796

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma

Authors

    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
    • Third Department of Internal Medicine, Faculty of Medical SciencesUniversity of Fukui
  • Takeshi Hisada
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Motoaki Hatori
    • Department of UrologyGunma University Graduate School of Medicine
  • Akio Koike
    • Central SupplyGunma University Hospital
  • Kikuo Hanabuchi
    • Central SupplyGunma University Hospital
  • Shinichi Matsuzaki
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Yosuke Kamide
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Mitsuyoshi Utsugi
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Haruka Aoki
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Reiko Yoshino
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Noriko Yanagitani
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Yasuhiko Koga
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Akihiro Ono
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Kyoichi Kaira
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Noriaki Sunaga
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Kunio Dobashi
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Takahiro Tsuburai
    • Clinical Research Center for Allergy and Rheumatology, National Hospital OrganizationSagamihara National Hospital
  • Kazuo Akiyama
    • Clinical Research Center for Allergy and Rheumatology, National Hospital OrganizationSagamihara National Hospital
  • Masanobu Yamada
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
  • Kazuhiro Suzuki
    • Department of UrologyGunma University Graduate School of Medicine
  • Masatomo Mori
    • Department of Medicine and Molecular ScienceGunma University Graduate School of Medicine
Original Research Paper

DOI: 10.1007/s00011-014-0753-1

Cite this article as:
Ishizuka, T., Hisada, T., Hatori, M. et al. Inflamm. Res. (2014) 63: 789. doi:10.1007/s00011-014-0753-1

Abstract

Objective and design

An open-label, non-randomized, single-arm study was performed to investigate the safety and efficacy of high-dose leukocytapheresis (pulse LCAP) for refractory asthma.

Subjects

Six patients who fulfilled the ATS workshop criteria for refractory asthma were enrolled and completed this clinical study.

Treatment

After 4 weeks of observation, pulse LCAP using a large LCAP filter, Cellsorba® CS-180S, was performed twice with a 1-week interval at a target dose of 5 L per treatment session.

Methods

The clinical response was assessed by monitoring the peak expiratory flow rate (PEFR) twice a day. The asthma control test (ACT) was used to evaluate the condition of asthma symptoms. The fraction of exhaled nitric oxide (FeNO) as a biomarker for eosinophilic airway inflammation was measured using a chemiluminescence analyzer.

Results

PEFR in the morning or the evening and the sum total of the score on the ACT were increased after two consecutive sessions of pulse LCAP. FeNO decreased after pulse LCAP.

Conclusions

The results suggest the efficacy of pulse LCAP for refractory asthma.

Keywords

Refractory asthmaLeukocytapheresis (LCAP)Peak expiratory flow rate (PEFR)Asthma control test (ACT)Fraction of exhaled nitric oxide (FeNO)

Copyright information

© Springer Basel 2014